Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
THTX Stock Forecast 2026-2027
$3.39
Current Price
$155.96M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to THTX Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
THTX Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+29.4%
1 Year Change
0.0%
Year-to-Date Change
-0.3%
From 52W High of $3.40
+202.7%
From 52W Low of $1.12
📊 TOP ANALYST CALLS
Did THTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Theratechnologies is one of their latest high-conviction picks.
Latest THTX Stock Price Targets & Analyst Predictions
THTX has shown a year-to-date change of 0.0% and a 1-year change of 29.4%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for THTX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
THTX Analyst Ratings
1
Buy
0
Hold
0
Sell
THTX Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $3.39
Latest THTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for THTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 3, 2025 | Jones Trading | Justin Walsh | Hold | Downgrade | $N/A |
| Oct 11, 2024 | Jones Trading | Justin Walsh | Hold | Downgrade | $N/A |
| Jul 17, 2023 | JonesTrading | Justin Walsh | Buy | Maintains | $3.00 |
| Jul 13, 2023 | Cantor Fitzgerald | Louis Chen | Overweight | Reiterates | $9.00 |
| Nov 17, 2022 | Cantor Fitzgerald | Louis Chen | Overweight | Initiates | $9.00 |
| Jul 29, 2021 | Canaccord Genuity | Edward Nash | Hold | Downgrade | $3.00 |
| Apr 19, 2021 | Canaccord Genuity | Buy | Maintains | $8.00 | |
| Apr 15, 2020 | Canaccord Genuity | Edward Nash | Buy | Maintains | $11.00 |
| Dec 11, 2019 | Mackie Research | Buy | Upgrade | $N/A |
Theratechnologies Inc. (THTX) Competitors
The following stocks are similar to Theratechnologies based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
THTX
Theratechnologies
mkt cap
155.96M
Theratechnologies Inc. (THTX) Financial Data
Theratechnologies Inc. has a market capitalization of $155.96M with a P/E ratio of -19.9x. The company generates $84.38M in trailing twelve-month revenue with a -10.9% profit margin.
Revenue growth is -19.5% quarter-over-quarter, while maintaining an operating margin of -10.7% and return on equity of +32.9%.
Valuation Metrics
Market Cap
$155.96M
Enterprise Value
$189.57M
P/E Ratio
-19.9x
PEG Ratio
0.0x
Price/Sales
1.8x
Growth & Margins
Revenue Growth (YoY)
-19.5%
Gross Margin
+73.5%
Operating Margin
-10.7%
Net Margin
-10.9%
EPS Growth
-19.5%
Financial Health
Cash/Price Ratio
+6.4%
Current Ratio
0.8x
Debt/Equity
-1.6x
ROE
+32.9%
ROA
+7.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Theratechnologies Inc. (THTX) Business Model
About Theratechnologies Inc.
What They Do
Develops innovative therapies for niche medical needs.
Business Model
The company focuses on developing and commercializing specialty biopharmaceuticals targeting unmet medical needs in endocrinology and oncology. It generates revenue primarily through the sale of its flagship products, Egrifta SV and Trogarzo, which address specific health issues related to HIV.
Additional Information
Theratechnologies operates mainly in North American and European markets, utilizing its expertise in peptide technology and biologics to enhance its product offerings. The company's commitment to research and development highlights its role in improving patient care and advancing biotechnological solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
103
CEO
Mr. Paul Lévesque
Country
Canada
IPO Year
N/A
Website
www.theratech.comTheratechnologies Inc. (THTX) Latest News & Analysis
Latest News
Quick Summary
Theratechnologies Inc. has completed a plan of arrangement, selling all shares to CB Biotechnology for $3.01 each, plus potential CVR payments of up to $1.19 per share based on future milestones.
Why It Matters
Theratechnologies' acquisition at $3.01 per share plus potential CVR payments indicates a liquidity event, impacting shareholder value and signaling future growth or risk based on performance milestones.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak
7 months ago
Quick Summary
Theratechnologies Inc. received final court approval for its arrangement with CB Biotechnology, following shareholder approval on September 12, 2025.
Why It Matters
Theratechnologies has secured court approval for a significant business arrangement, boosting investor confidence and potentially enhancing its market position and financial outlook.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak
7 months ago
Quick Summary
Theratechnologies Inc. shareholders approved a plan of arrangement with CB Biotechnology, LLC, an affiliate of Future Pak, under Quebec's Business Corporations Act.
Why It Matters
The approval of the arrangement with CB Biotechnology signals a strategic partnership that could enhance Theratechnologies’ growth prospects and market position, potentially impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Theratechnologies Inc. (TH:CA) Special Meeting Of Shareholders Of Theratechnologies Call (Transcript)
7 months ago
Quick Summary
Theratechnologies Inc. held a Special Meeting of Shareholders, featuring Chair Frank Holler and CFO Philippe Dubuc. The meeting was recorded for future reference.
Why It Matters
The special meeting indicates potential strategic decisions or updates that could impact Theratechnologies' stock performance, influencing investor sentiment and market reactions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
EGRIFTA WR™ provides weekly reconstitution and a lower daily injection volume than EGRIFTA SV®, enhancing convenience for users.
Why It Matters
EGRIFTA WR™'s convenience and lower injection volume may enhance patient adherence, potentially boosting sales and market share, positively impacting investor outlook.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Theratechnologies Inc. announced that ISS and Glass Lewis recommended shareholders vote "FOR" the Arrangement Resolution for a plan involving CB Biotechnology, LLC.
Why It Matters
The endorsement from ISS and Glass Lewis for Theratechnologies' arrangement may boost shareholder confidence, potentially impacting stock price and market perception positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About THTX Stock
What is Theratechnologies Inc.'s (THTX) stock forecast for 2026?
Analyst forecasts for Theratechnologies Inc. (THTX) are not currently available. The stock is trading at $3.39.
Is THTX stock a good investment in 2026?
According to current analyst ratings, THTX has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.39. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for THTX stock?
Price predictions from Wall Street analysts for THTX are not currently available. The stock is trading at $3.39.
What is Theratechnologies Inc.'s business model?
The company focuses on developing and commercializing specialty biopharmaceuticals targeting unmet medical needs in endocrinology and oncology. It generates revenue primarily through the sale of its flagship products, Egrifta SV and Trogarzo, which address specific health issues related to HIV.
What is the highest forecasted price for THTX Theratechnologies Inc.?
Price targets from Wall Street analysts for THTX are not currently available. The stock is trading at $3.39.
What is the lowest forecasted price for THTX Theratechnologies Inc.?
Price targets from Wall Street analysts for THTX are not currently available. The stock is trading at $3.39.
What is the overall THTX consensus from analysts for Theratechnologies Inc.?
The overall analyst consensus for THTX is bullish. Out of 4 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are THTX stock price projections?
Stock price projections, including those for Theratechnologies Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 7, 2026 7:36 PM UTC